<p>Order of the National Green Tribunal in the matter of News item titled "Impact of Pharmaceutical toxicity on the environment and its regulatory aspects" appearing in Current Science dated
Dora Akunyili is director-general of Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC). Since her appointment in 2001, she has led a successful crusade against counterfeit pharmaceuticals, which are responsible for millions of deaths worldwide each year.
Ranbaxy on Tuesday said that it has entered into a business alliance with Orchid Chemicals & Pharmaceuticals, involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (raw materials). However, sources said the option of acquiring additional equity in Orchid, and announcing an open offer at a later stage, could not be ruled out.
Ranbaxy Laboratories (Ranbaxy) and Orchid Chemicals & Pharmaceuticals (Orchid) have announced that they have entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (APIs). Additionally, this agreement would establish a framework for enhanced future co-operation between the two companies.
A parliamentary panel has pulled up the Department of Chemicals and Petrochemicals for delay in finalising the National Pharmaceutical Policy, 2006. In its report, the Parliamentary Standing Committee on Chemicals and Fertilizers has observed that despite its recommendation for finalising the policy, the department remained static on such a crucial issue. The recommendation was made in the 20th report (2006-07), which is an action-taken report of the 7th Report of the committee in 2005-06.
The Parliamentary Standing Committee on Chemical and Fertiliser has slammed the Department of Chemicals and Petrochemicals over the delay in finalising National Pharmaceutical Policy (NPP) 2006. The policy, aimed at making drugs cheaper, has been delayed due to strong opposition from the industry. While the policy will bring more number of drugs under price control, the industry wants the Government to encourage free market pricing. The policy was referred to a Group of Ministers which is yet to take a decision.
Clinical research organisation Siro Clinpharm Pvt Ltd has acquired 100 per cent equity in Germany-based Omega Mediation Group in an all-cash deal, but for an undisclosed sum. The acquisition marks Siro Clinpharm's entry into Europe, said Dr Chetan Tamhankar, Chief Operating Officer, Siro Clinpharm. Omega has around 120 people, across its operations in Greece, Estonia and Israel. And there will be no change in the management or employee structure as the operations expand, he said.
Sixteen months after it was set up, an inter-ministerial group is set to finalise a new pharma policy for the country. A group of ministers (GoM) headed by Agriculture Minister Sharad Pawar is scheduled to meet on April 30 to finalise its recommendations for a policy that would attempt to balance the interests of the common man and the industry. The draft pharma policy before the GoM has called for increasing the span of price control on the Rs 55,000-crore domestic drug market from the current 20 per cent to over 35 per cent.
Ranbaxy is understood to be finalizing a plan to announce an open offer for Chennai-based Orchid Chemicals. Solrex, believed to be backed by Ranbaxy's promoters, has already bought 11.3% stake in Orchid, and according to market sources, later upped it to 14.7%. This is marginally less than the 15% limit required to make an open offer for an additional 20% stake in the company. When contacted Ranbaxy chief executive officer and managing director, Malvinder M Singh said
The country's largest drug maker Ranbaxy Laboratories today announced the launch of bonista teriparatide injection used in the treatment of osteoporosis (thinning of bones) in collaboration with Hyd
Country's largest drug maker, Ranbaxy, on Thursday announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech. BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio-generic product, the company said in a filing to the BSE.
